Compare JMM & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | JMM | COCH |
|---|---|---|
| Founded | 1988 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Blank Checks |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.6M | 51.0M |
| IPO Year | N/A | 2021 |
| Metric | JMM | COCH |
|---|---|---|
| Price | $5.77 | $0.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 8.3K | ★ 162.2K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 5.44% | N/A |
| EPS Growth | N/A | ★ 17.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $241,000.00 |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $5.67 | $0.36 |
| 52 Week High | $6.52 | $1.89 |
| Indicator | JMM | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 46.19 | 54.79 |
| Support Level | $5.77 | $0.63 |
| Resistance Level | $5.88 | $0.88 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 46.15 | 61.33 |
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.